13 results on '"Melum, E"'
Search Results
2. Long-term survival after liver transplantation for alcohol-related liver disease in the Nordic countries.
- Author
-
Bergsmark T, Engesæter LK, Rasmussen A, Bennet W, Nordin A, Pall V, Line PD, Ericzon BG, and Melum E
- Subjects
- Humans, Male, Female, Middle Aged, Follow-Up Studies, Scandinavian and Nordic Countries epidemiology, Time Factors, Retrospective Studies, Liver Transplantation, Liver Diseases surgery, Liver Diseases, Alcoholic surgery
- Abstract
Objectives: Alcohol-related liver disease (ALD) is among the most common indications for liver transplantation (LTX) in Europe and North America, with good five-year survival rates post-LTX. Here we evaluated survival up to and beyond 20 years after LTX for patients with ALD compared to a comparison group., Methods: Patients with ALD and a comparison group transplanted in the Nordic countries between 1982 and 2020 were included. Data were analyzed using descriptive statistics, Kaplan-Meier curves and predictors of survival were assessed with Cox-regressions., Results: 831 patients with ALD and 2979 patients in the comparison group were included in the study. Patients with ALD were older at the time of LTX ( p < .001) and more likely to be male ( p < .001). The estimated median follow-up time was 9.1 years for the ALD-group and 11.1 years for the comparison group. 333 (40.1%) patients with ALD and 1010 (33.9%) patients in the comparison group died during follow-up. The overall survival was impaired for patients with ALD compared to the comparison group ( p < .001) and was evident for male and female patients, patients transplanted before and after 2005, and observed in all age-groups except patients over 60 years. Age at transplant, waiting time, year of LTX and country of LTX were associated with decreased survival after LTX for patients with ALD., Conclusions: Patients with ALD have a decreased long-term survival following LTX. This difference was evident in most sub-groups of patients and warrants close follow-up of liver transplanted patients with ALD with focus on risk reduction.
- Published
- 2023
- Full Text
- View/download PDF
3. Liver Transplantation for Acute Intermittent Porphyria.
- Author
-
Lissing M, Nowak G, Adam R, Karam V, Boyd A, Gouya L, Meersseman W, Melum E, Ołdakowska-Jedynak U, Reiter FP, Colmenero J, Sanchez R, Herden U, Langendonk J, Ventura P, Isoniemi H, Boillot O, Braun F, Perrodin S, Mowlem E, and Wahlin S
- Subjects
- Female, Humans, Male, Quality of Life, Registries, Retrospective Studies, Liver Transplantation adverse effects, Porphyria, Acute Intermittent complications
- Abstract
Recurrent attacks of acute intermittent porphyria (AIP) result in poor quality of life and significant risks of morbidity and mortality. Liver transplantation (LT) offers a cure, but published data on outcomes after LT are limited. We assessed the pretransplant characteristics, complications, and outcomes for patients with AIP who received a transplant. Data were collected retrospectively from the European Liver Transplant Registry and from questionnaires sent to identified transplant and porphyria centers. We studied 38 patients who received transplants in 12 countries from 2002 to 2019. Median age at LT was 37 years (range, 18-58), and 34 (89%) of the patients were women. A total of 9 patients died during follow-up, and 2 patients were retransplanted. The 1-year and 5-year overall survival rates were 92% and 82%, which are comparable with other metabolic diseases transplanted during the same period. Advanced pretransplant neurological impairment was associated with increased mortality. The 5-year survival rate was 94% among 19 patients with moderate or no neuropathy at LT and 83% among 10 patients with severe neuropathy (P = 0.04). Pretransplant renal impairment was common. A total of 19 (51%) patients had a GFR < 60 mL/minute. Although few patients improved their renal function after LT, neurological impairments improved, and no worsening of neurological symptoms was recorded. No patient had AIP attacks after LT, except for a patient who received an auxiliary graft. LT is a curative treatment option for patients with recurrent attacks of AIP. Severe neuropathy and impaired renal function are common and increase the risk for poor outcomes. If other treatment options fail, an evaluation for LT should be performed early., (Copyright © 2020 The Authors. Liver Transplantation published by Wiley Periodicals LLC on behalf of American Association for the Study of Liver Diseases.)
- Published
- 2021
- Full Text
- View/download PDF
4. Nonalcoholic fatty liver disease is an increasing indication for liver transplantation in the Nordic countries.
- Author
-
Holmer M, Melum E, Isoniemi H, Ericzon BG, Castedal M, Nordin A, Aagaard Schultz N, Rasmussen A, Line PD, Stål P, Bennet W, and Hagström H
- Subjects
- Adult, Cohort Studies, Female, Humans, Liver Cirrhosis mortality, Liver Cirrhosis surgery, Male, Middle Aged, Multivariate Analysis, Non-alcoholic Fatty Liver Disease mortality, Obesity, Prevalence, Registries, Risk Factors, Scandinavian and Nordic Countries epidemiology, Survival Analysis, Time Factors, Waiting Lists, Liver Cirrhosis congenital, Liver Transplantation statistics & numerical data, Non-alcoholic Fatty Liver Disease surgery
- Abstract
Background & Aims: Nonalcoholic fatty liver disease(NAFLD) is the second most common cause of liver transplantation in the US. Data on NAFLD as a liver transplantation indication from countries with lower prevalences of obesity are lacking. We studied the temporal trends of NAFLD as an indication for liver transplantation in the Nordic countries, and compared outcomes for patients with NAFLD to patients with other indications for liver transplantation., Method: Population-based cohort study using data from the Nordic Liver Transplant Registry on adults listed for liver transplantation between 1994 and 2015. NAFLD as the underlying indication for liver transplantation was defined as a listing diagnosis of NAFLD/nonalcoholic steatohepatitis, or cryptogenic cirrhosis with a body mass index ≥25 kg/m
2 and absence of other liver diseases. Waiting time for liver transplantation, mortality and withdrawal from the transplant waiting list were registered. Survival after liver transplantation was calculated using multivariable Cox regression, adjusted for age, sex, body mass index and model for end-stage liver disease., Results: A total of 4609 patients listed for liver transplantation were included. NAFLD as the underlying indication for liver transplantation increased from 2.0% in 1994-1995 to 6.2% in 2011-2015 (P = .01) and was the second most rapidly increasing indication. NAFLD patients had higher age, model for end-stage liver disease and body mass index when listed for liver transplantation, but overall survival after liver transplantation was comparable to non--NAFLD patients (aHR 1.03, 95% CI 0.70-1.53 P = .87)., Conclusion: NAFLD is an increasing indication for liver transplantation in the Nordic countries. Despite more advanced liver disease, NAFLD patients have a comparable survival to other patients listed for liver transplantation., (© 2018 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.)- Published
- 2018
- Full Text
- View/download PDF
5. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei in a liver-transplanted patient: a case report.
- Author
-
Thorgersen EB, Melum E, Folseraas T, Larsen SG, and Line PD
- Subjects
- Antineoplastic Agents, Alkylating administration & dosage, Bile Duct Neoplasms surgery, Cholangiocarcinoma surgery, Cholangitis, Sclerosing surgery, Female, Humans, Liver blood supply, Liver diagnostic imaging, Middle Aged, Mitomycin administration & dosage, Pancreaticoduodenectomy, Peritoneal Neoplasms diagnosis, Peritoneal Neoplasms drug therapy, Prognosis, Pseudomyxoma Peritonei diagnosis, Pseudomyxoma Peritonei drug therapy, Cytoreduction Surgical Procedures, Hyperthermia, Induced, Liver Transplantation, Peritoneal Neoplasms surgery, Pseudomyxoma Peritonei surgery
- Abstract
Background: Diagnostic work-ups in transplanted immunosuppressed patients are a challenge as non-specific findings may be interpreted as transplant-related complications. If the disease in question is rare and slowly developing like pseudomyxoma peritonei (PMP), it is even more difficult. Cytoreductive surgery (CRS) and subsequent hyperthermic intraperitoneal chemotherapy (HIPEC) is the recommended treatment for PMP even with extensive peritoneal spread. CRS-HIPEC for PMP after liver transplantation (LTX) has not been described before., Case Presentation: A 48-year-old female patient with end-stage primary sclerosing cholangitis (PSC) underwent orthotopic LTX and subsequent pancreaticoduodenectomy after the finding of cholangiocarcinoma in situ in the native common bile duct. Ten years after the transplantation, she developed symptoms and signs suspected to represent graft-related complications. An extensive work-up revealed PMP. Upon reassessment, a cystic mass near the coecum could be seen on computed tomography scan 1 year after transplantation. The multidisiplinary team was hesitant to accept the patient for CRS-HIPEC because of extensive PMP and possible risk to the graft. However, she was eventually accepted and underwent the procedure. The Peritoneal Cancer Index (PCI) was 28 of 39, and surgical debulking was performed followed by HIPEC. The transplant control 2 months after surgery showed no harm to the graft., Conclusions: Previous LTX should not exclude the possibility for CRS-HIPEC in PMP, even with extensive burden of disease.
- Published
- 2018
- Full Text
- View/download PDF
6. Liver transplantation in the Nordic countries - An intention to treat and post-transplant analysis from The Nordic Liver Transplant Registry 1982-2013.
- Author
-
Fosby B, Melum E, Bjøro K, Bennet W, Rasmussen A, Andersen IM, Castedal M, Olausson M, Wibeck C, Gotlieb M, Gjertsen H, Toivonen L, Foss S, Makisalo H, Nordin A, Sanengen T, Bergquist A, Larsson ME, Soderdahl G, Nowak G, Boberg KM, Isoniemi H, Keiding S, Foss A, Line PD, Friman S, Schrumpf E, Ericzon BG, Höckerstedt K, and Karlsen TH
- Subjects
- Adult, Aged, Female, Humans, Kidney Failure, Chronic mortality, Male, Middle Aged, Reoperation, Retrospective Studies, Scandinavian and Nordic Countries epidemiology, Survival Rate trends, Intention to Treat Analysis methods, Kidney Failure, Chronic surgery, Liver Transplantation statistics & numerical data, Registries, Tissue and Organ Procurement methods, Waiting Lists
- Abstract
Aim and Background: The Nordic Liver Transplant Registry (NLTR) accounts for all liver transplants performed in the Nordic countries since the start of the transplant program in 1982. Due to short waiting times, donor liver allocation has been made without considerations of the model of end-stage liver disease (MELD) score. We aimed to summarize key outcome measures and developments for the activity up to December 2013., Materials and Methods: The registry is integrated with the operational waiting-list and liver allocation system of Scandiatransplant (www.scandiatransplant.org) and accounted at the end of 2013 for 6019 patients out of whom 5198 were transplanted. Data for recipient and donor characteristics and relevant end-points retransplantation and death are manually curated on an annual basis to allow for statistical analysis and the annual report., Results: Primary sclerosing cholangitis, acute hepatic failure, alcoholic liver disease, primary biliary cirrhosis and hepatocellular carcinoma are the five most frequent diagnoses (accounting for 15.3%, 10.8%, 10.6%, 9.3% and 9.0% of all transplants, respectively). Median waiting time for non-urgent liver transplantation during the last 10-year period was 39 days. Outcome has improved over time, and for patients transplanted during 2004-2013, overall one-, five- and 10-year survival rates were 91%, 80% and 71%, respectively. In an intention-to-treat analysis, corresponding numbers during the same time period were 87%, 75% and 66%, respectively., Conclusion: The liver transplant program in the Nordic countries provides comparable outcomes to programs with a MELD-based donor liver allocation system. Unique features comprise the diagnostic spectrum, waiting times and the availability of an integrated waiting list and transplant registry (NLTR).
- Published
- 2015
- Full Text
- View/download PDF
7. Continuous molecular adsorbent recirculating system treatment in 69 patients listed for liver transplantation.
- Author
-
Olin P, Hausken J, Foss A, Karlsen TH, Melum E, and Haugaa H
- Subjects
- Adolescent, Adult, Aged, Child, Child, Preschool, Female, Humans, Infant, Intensive Care Units, Logistic Models, Male, Middle Aged, Retrospective Studies, Tertiary Care Centers, Treatment Outcome, Young Adult, Acute-On-Chronic Liver Failure therapy, End Stage Liver Disease therapy, Liver Transplantation methods, Renal Dialysis methods
- Abstract
Objective: The molecular adsorbent recirculating system (MARS) is used to purify blood from albumin-bound toxins in patients with liver failure. However, the application of MARS has not demonstrated improved survival in randomized clinical trials and the clinical utility has not been finally established. In our department, the use of MARS is now restricted to the most critically ill patients with acute or acute on chronic liver failure., Material and Methods: Since 2005, we have treated 69 patients (30 males/39 females with median age of 49 years ranging from 1 months to 70 years) listed for liver transplantation (LT) with MARS. Median model of end-stage liver disease score in patients older than 12 years of age (n = 56) was 33 (interquartile range 26-39). The flow rate was 35-40 mL/kg/h and treatment kits were changed every 8-12 h. The patients were treated for a median of 27 h (range 1-144 h)., Results: Fifty-six patients (81%) were transplanted. Nine died before they could be transplanted, and four patients recovered without transplantation. Forty-six (82%) of the transplanted patients were alive 30 days after transplantation. Ammonium decreased modestly from a median of 148 to 124 µM (p = 0.03) during MARS treatment. We detected worsening of coagulopathy with significant decreases in platelet count and fibrinogen concentrations, and increase in International Normalized Ratio. Phosphate and magnesium decreased significantly during MARS treatment., Conclusion: Continuous MARS therapy may bridge liver failure patients to LT under close observation and treatment of coagulopathy and electrolyte disturbances.
- Published
- 2015
- Full Text
- View/download PDF
8. HLA variants related to primary sclerosing cholangitis influence rejection after liver transplantation.
- Author
-
Fosby B, Næss S, Hov JR, Traherne J, Boberg KM, Trowsdale J, Foss A, Line PD, Franke A, Melum E, Scott H, and Karlsen TH
- Subjects
- Adolescent, Adult, Aged, Alleles, Cholangitis, Sclerosing immunology, End Stage Liver Disease immunology, Female, Genotype, Graft Survival, HLA Antigens immunology, Humans, Immunohistochemistry, Male, Middle Aged, Receptors, KIR genetics, Retrospective Studies, Risk Factors, Treatment Outcome, Young Adult, Cholangitis, Sclerosing genetics, End Stage Liver Disease surgery, Graft Rejection, HLA Antigens genetics, Liver Transplantation
- Abstract
Aim: To investigate influence of human leukocyte antigen (HLA) and killer immunoglobuline-like receptor (KIR) genotypes on risks of acute rejection (AR) after liver transplantation (LTX)., Methods: In this retrospective study we included 143 adult donor-recipient pairs with a minimum of 6 mo follow-up after LTX for whom DNA was available from both donor and recipients. Clinical data, all early complications including episodes and severity of AR and graft/patient survival were registered. The diagnosis of AR was based on clinical, biochemical and histological criteria. All suspected episodes of AR were biopsy confirmed. Key classical HLA loci (HLA-A, HLA-B, HLA-C and HLA-DRB1) were genotyped using Sanger sequencing. 16 KIR genes were genotyped using a novel real time PCR approach which allows for determination of the diploid copy number of each KIR gene. Immunohistochemical staining for T (CD3), B (CD20) and natural killer (NK) cells (CD56 and CD57) were performed on liver biopsies from 3 different patient groups [primary sclerosing cholangitis (PSC), primary biliary cirrhosis and non-autoimmune liver disease], 10 in each group, with similar grade of AR., Results: Fourty-four (31%) patients were transplanted on the basis of PSC, 40% of them had AR vs 24% in the non-PSC group (P = 0.04). No significant impact of donor-recipient matching for HLA and KIR genotypes was detected. In the overall recipient population an increased risk of AR was detected for HLA-B*08 (P = 0.002, OR = 2.5; 95%CI: 1.4-4.6), HLA-C*07 (P = 0.001, OR = 2.4; 95%CI: 1.4-4.0) and HLA-DRB1*03 (P = 0.03, OR = 1.9; 95%CI: 1.0-3.3) and a decreased risk for HLA-DRB1*04 (P = 0.001, OR = 0.2; 95%CI: 0.1-0.5). For HLA-B*08, HLA-C*07 and DRB1*04 the associations remained evident in a subgroup analysis of non-PSC recipients (P = 0.04, P = 0.003 and P = 0.02, respectively). In PSC recipients corresponding P values were 0.002, 0.17 and 0.01 for HLA-B*08, HLA-C*07 and DRB1*04, respectively. A dosage effect of AR prevalence according to the PSC associated HLA alleles was also notable in the total recipient population. For HLA-B*08 the frequency of AR was 56% in HLA-B*08 homozygous recipients, 39% in heterozygous recipients and 21% in recipients lacking HLA-B*08 (P = 0.02). The same was observed for the HLA-C*07 allele with AR in 57%, 27% and 18% in recipients being homozygous, heterozygous and lacking HLA-C*07 respectively (P = 0.003). Immunohistochemical analysis showed similar infiltration of T, B and NK cells in biopsies with AR in all three groups., Conclusion: We found significant associations between the PSC-associated HLA-B*08, HLA-C*07, HLA-DRB1*03 and HLA-DRB1*04 alleles and risk of AR in liver transplant recipients.
- Published
- 2014
- Full Text
- View/download PDF
9. Recurrence and rejection in liver transplantation for primary sclerosing cholangitis.
- Author
-
Fosby B, Karlsen TH, and Melum E
- Subjects
- Animals, Cholangiography, Cholangitis, Sclerosing epidemiology, Cholangitis, Sclerosing pathology, Diagnosis, Differential, Graft Rejection epidemiology, Graft Rejection physiopathology, Humans, Liver pathology, Liver surgery, Postoperative Complications, Recurrence, Risk Factors, Survival Analysis, Cholangitis, Sclerosing prevention & control, Cholangitis, Sclerosing surgery, Graft Rejection pathology, Liver Transplantation
- Abstract
Primary sclerosing cholangitis (PSC) is a chronic progressive inflammatory disease affecting the bile ducts, leading to fibrosis and eventually cirrhosis in most patients. Its etiology is unknown and so far no effective medical therapy is available. Liver transplantation (LTX) is the only curative treatment and at present PSC is the main indication for LTX in the Scandinavian countries. Close to half of the PSC patients experience one or more episodes of acute cellular rejection (ACR) following transplantation and approximately 1/5 of the transplanted patients develop recurrent disease in the graft. In addition, some reports indicate that ACR early after LTX for PSC can influence the risk for recurrent disease. For these important post-transplantation entities affecting PSC patients, we have reviewed the current literature on epidemiology, pathogenesis, treatment and the possible influence of rejection on the risk of recurrent disease in the allograft.
- Published
- 2012
- Full Text
- View/download PDF
10. Hepatitis C impairs survival following liver transplantation irrespective of concomitant hepatocellular carcinoma.
- Author
-
Melum E, Friman S, Bjøro K, Rasmussen A, Isoniemi H, Gjertsen H, Bäckman L, Oksanen A, Olausson M, Duraj FF, and Ericzon BG
- Subjects
- Adult, Carcinoma, Hepatocellular etiology, Case-Control Studies, Comorbidity, Female, Hepatitis C etiology, Humans, Liver Cirrhosis, Liver Transplantation mortality, Male, Middle Aged, Scandinavian and Nordic Countries epidemiology, Survival Rate, Carcinoma, Hepatocellular mortality, Hepatitis C complications, Hepatitis C mortality, Liver Transplantation adverse effects
- Abstract
Background/aims: Liver transplantation (LTX) is the only curative treatment for end-stage liver disease caused by hepatitis C (HCV). Hepatocellular carcinoma (HCC) is common in patients with HCV cirrhosis., Methods: Two hundred and eighty-two HCV patients listed for LTX in the Nordic countries in a 17-year period were included. For comparison a group of patients with non-viral chronic liver disease (n=1552) was used., Results: Two hundred and fifty-three (90%) patients received a first liver allograft. HCC was found in 38% of the explanted livers. Survival at 1, 3 and 5years was 82%, 69% and 61% vs. 85%, 80% and 76% for the comparison group (p<0.0001), this survival difference was also evident when excluding patients with HCC (p=0.007). HCV patients with HCC had 1, 3 and 5year survival of 73%, 52% and 46% compared with 88%, 80% and 71% for the HCV patients without HCC (p=0.0005). In an intention-to-treat analysis (from time of acceptance to the waiting list) HCV was also associated with an impaired survival., Conclusions: HCV cirrhosis, which is now also an important indication for LTX in the Nordic countries, and significantly impairs survival following LTX. Concomitant HCC and donor age are the two most important factors contributing to an impaired survival.
- Published
- 2007
- Full Text
- View/download PDF
11. Liver TX for hepatitis C cirrhosis in a low prevalence population: risk factors and status at evaluation.
- Author
-
Melum E, Schrumpf E, and Bjøro K
- Subjects
- Adult, Hepatitis C epidemiology, Humans, Liver Cirrhosis epidemiology, Liver Transplantation mortality, Norway epidemiology, Prevalence, Reoperation, Survival Analysis, Treatment Outcome, Hepatitis C surgery, Liver Cirrhosis surgery, Liver Cirrhosis virology, Liver Transplantation statistics & numerical data
- Abstract
Objective: Hepatitis C virus (HCV) cirrhosis is the most common indication for liver transplantation (LTX) world-wide. The prevalence of HCV infections is much lower in Norway than in most other countries from which data on HCV infection and liver transplantation have been published., Material and Methods: Patients with HCV infection referred for evaluation of a possible LTX between 1990 and 2005 were included in the study. Their clinical status, biochemical parameters and risk factors were recorded. All patients were followed until 1 January 2005 irrespective of transplantation status., Results: Fifty-one patients were included; 80% were males and 18% were non-Caucasians. Previous intravenous drug abuse (28%) and exposure to contaminated IgG products (15%) were the most common routes of infection. In 45/51 (88%) of the evaluated patients at least one risk factor for rapid progression of HCV disease was identified. Twenty-seven patients were accepted on the waiting list. The MELD (model for endstage liver disease) score for the accepted patients was significantly higher than that for the patients who were not listed because they were found to be too healthy (18.4 versus 12.1, p<0.01). Twenty-four patients (89% of those listed) received a liver allograft; their 1-, 3- and 5-year survival rates following LTX were 81%, 68% and 68%, respectively. Two patients needed a second transplantation., Conclusions: A low number of HCV-infected patients have so far been evaluated for LTX in Norway. The present study demonstrates that almost all of the HCV patients progressing to cirrhosis and being evaluated for LTX in Norway have additional risk factors for development of cirrhosis.
- Published
- 2006
- Full Text
- View/download PDF
12. Genetic association analysis identifies variants associated with disease progression in primary sclerosing cholangitis
- Author
-
Martina Sterneck, Wolfgang Lieb, Christian Rust, Tom H. Karlsen, Massimo Pinzani, Erik Schrumpf, John E. Eaton, Gideon M. Hirschfield, Christoph Schramm, Richard Sandford, Ulrich Beuers, Andrew Mason, Espen Melum, Daniel Gotthardt, A. Boudewijn de Vries, I. Franceschet, Konstantinos N. Lazaridis, Floris Imhann, Marco Carbone, Pietro Invernizzi, Mark S. Silverberg, Simon Hohenester, Maria Consiglia Bragazzi, Andreas Teufel, Bart van Hoek, Martti Färkkilä, Einar Bjornsson, Cyriel Y. Ponsioen, Brijesh Srivastava, Joanne Verheij, Roger W. Chapman, Krista Rombouts, Niklas K. Björkström, Johannes R. Hov, Weiwei Wang, F. Sampaziotis, Ludovic Vallier, Albert Parés, Eleonora A. M. Festen, Kristian Holm, Kalliopi Zachou, Katrin Böttcher, Christopher L. Bowlus, Xiaojun Jiang, Trine Folseraas, Elisabeth M.G. de Vries, Simon M. Rushbrook, Piotr Milkiewicz, Carl A. Anderson, Georgios N. Dalekos, David Ellinghaus, Hanns-Ulrich Marschall, Rinse K. Weersma, Marco Marzioni, Olivier Chazouillères, Domenico Alvaro, Christian Rupp, Angela M. Cheung, Jimmy Z. Liu, Brian D. Juran, Michael P. Manns, Rudi Alberts, Bertus Eksteen, Tobias J. Weismüller, Graeme J.M. Alexander, Annarosa Floreani, Tobias Müller, Stefan Schreiber, Andre Franke, Elizabeth C. Goode, Henrike Lenzen, Arnau Vich Vila, Annika Bergquist, Kirsten Muri Boberg, Groningen Institute for Gastro Intestinal Genetics and Immunology (3GI), Gastroenterology and Hepatology, AGEM - Amsterdam Gastroenterology Endocrinology Metabolism, Graduate School, Pathology, Alberts, R, De Vries, E, Goode, E, Jiang, X, Sampaziotis, F, Rombouts, K, Böttcher, K, Folseraas, T, Weismüller, T, Mason, A, Wang, W, Alexander, G, Alvaro, D, Bergquist, A, Björkström, N, Beuers, U, Björnsson, E, Boberg, K, Bowlus, C, Bragazzi, M, Carbone, M, Chazouillères, O, Cheung, A, Dalekos, G, Eaton, J, Eksteen, B, Ellinghaus, D, Färkkilä, M, Festen, E, Floreani, A, Franceschet, I, Gotthardt, D, Hirschfield, G, Hoek, B, Holm, K, Hohenester, S, Hov, J, Imhann, F, Invernizzi, P, Juran, B, Lenzen, H, Lieb, W, Liu, J, Marschall, H, Marzioni, M, Melum, E, Milkiewicz, P, Müller, T, Pares, A, Rupp, C, Rust, C, Sandford, R, Schramm, C, Schreiber, S, Schrumpf, E, Silverberg, M, Srivastava, B, Sterneck, M, Teufel, A, Vallier, L, Verheij, J, Vila, A, Vries, B, Zachou, K, Chapman, R, Manns, M, Pinzani, M, Rushbrook, S, Lazaridis, K, Franke, A, Anderson, C, Karlsen, T, Ponsioen, C, Weersma, R, Centre of Excellence in Complex Disease Genetics, Doctoral Programme in Drug Research, Department of Medicine, Clinicum, Gastroenterologian yksikkö, HUS Abdominal Center, and Universitat de Barcelona
- Subjects
Male ,0301 basic medicine ,Oncology ,Candidate gene ,Cholangitis ,medicine.medical_treatment ,Medizin ,Trasplantament hepàtic ,Genome-wide association study ,Kaplan-Meier Estimate ,LIVER FIBROSIS ,Liver transplantation ,Bioinformatics ,Sclerosing ,Oral and gastrointestinal ,Primary sclerosing cholangitis ,genetics ,liver transplantation ,Cohort Studies ,ACTIVATION ,0302 clinical medicine ,MED/12 - GASTROENTEROLOGIA ,MULTIPLE ,2.1 Biological and endogenous factors ,EPIDEMIOLOGY ,Aetiology ,CIRRHOSIS ,Bilious diseases and biliousness ,Liver Disease ,digestive, oral, and skin physiology ,Gastroenterology ,Single Nucleotide ,Primary sclerosing cholangiti ,Middle Aged ,3. Good health ,ULCERATIVE-COLITIS ,Disease Progression ,Female ,030211 gastroenterology & hepatology ,Adult ,medicine.medical_specialty ,Cholangitis, Sclerosing ,Chronic Liver Disease and Cirrhosis ,Clinical Sciences ,Malalties del tracte biliar ,Single-nucleotide polymorphism ,HEPATIC STELLATE CELLS ,Polymorphism, Single Nucleotide ,International PSC Study Group ,Article ,Paediatrics and Reproductive Medicine ,03 medical and health sciences ,Rare Diseases ,Clinical Research ,Internal medicine ,Genetics ,medicine ,Humans ,Polymorphism ,GENOME-WIDE ASSOCIATION ,Allele ,Digestive Diseases - (Gallbladder) ,Survival analysis ,Proportional Hazards Models ,MALIGNANCY ,The UK PSC Consortium ,Transplantation ,Gastroenterology & Hepatology ,business.industry ,Proportional hazards model ,medicine.disease ,RISK LOCI ,Logistic Models ,030104 developmental biology ,3121 General medicine, internal medicine and other clinical medicine ,genetic ,Hepatic transplantation ,Thrombospondins ,Digestive Diseases ,business ,Genètica - Abstract
ObjectivePrimary sclerosing cholangitis (PSC) is a genetically complex, inflammatory bile duct disease of largely unknown aetiology often leading to liver transplantation or death. Little is known about the genetic contribution to the severity and progression of PSC. The aim of this study is to identify genetic variants associated with PSC disease progression and development of complications.DesignWe collected standardised PSC subphenotypes in a large cohort of 3402 patients with PSC. After quality control, we combined 130 422 single nucleotide polymorphisms of all patients—obtained using the Illumina immunochip—with their disease subphenotypes. Using logistic regression and Cox proportional hazards models, we identified genetic variants associated with binary and time-to-event PSC subphenotypes.ResultsWe identified genetic variant rs853974 to be associated with liver transplant-free survival (p=6.07×10–9). Kaplan-Meier survival analysis showed a 50.9% (95% CI 41.5% to 59.5%) transplant-free survival for homozygous AA allele carriers of rs853974 compared with 72.8% (95% CI 69.6% to 75.7%) for GG carriers at 10 years after PSC diagnosis. For the candidate gene in the region, RSPO3, we demonstrated expression in key liver-resident effector cells, such as human and murine cholangiocytes and human hepatic stellate cells.ConclusionWe present a large international PSC cohort, and report genetic loci associated with PSC disease progression. For liver transplant-free survival, we identified a genome-wide significant signal and demonstrated expression of the candidate gene RSPO3 in key liver-resident effector cells. This warrants further assessments of the role of this potential key PSC modifier gene.
- Published
- 2017
13. Characterization of animal models for primary sclerosing cholangitis (PSC)
- Author
-
Carolin Lackner, Verena Keitel, Peter Fickert, Michael Manns, Gideon M. Hirschfield, Michael Trauner, Bertus Eksteen, Christoph Schramm, Tom H. Karlsen, Hanns-Ulrich Marschall, Arthur Kaser, Chantal Housset, Ulrich Beuers, Mario Strazzabosco, Espen Melum, Marion J. Pollheimer, Fickert, P, Pollheimer, M, Beuers, U, Lackner, C, Hirschfield, G, Housset, C, Keitel, V, Schramm, C, Marschall, H, Karlsen, T, Melum, E, Kaser, A, Eksteen, B, Strazzabosco, M, Manns, M, and Trauner, M
- Subjects
Biliary fibrosis ,medicine.medical_specialty ,medicine.medical_treatment ,Cholangitis, Sclerosing ,Bile acid ,Liver transplantation ,Inflammatory bowel disease ,Gastroenterology ,Article ,Primary sclerosing cholangitis ,Cholestasis ,MED/12 - GASTROENTEROLOGIA ,Internal medicine ,medicine ,Animals ,Humans ,Animal model ,Intensive care medicine ,Anti-neutrophil cytoplasmic antibody ,Hepatology ,business.industry ,Cholangiopathie ,Cholestatic liver disease ,Primary sclerosing cholangiti ,medicine.disease ,Ulcerative colitis ,Bile acids ,Disease Models, Animal ,Biliary fibrosi ,Position paper ,business ,Cholangiopathies - Abstract
SummaryPrimary sclerosing cholangitis (PSC) is a chronic cholangiopathy characterized by biliary fibrosis, development of cholestasis and end stage liver disease, high risk of malignancy, and frequent need for liver transplantation. The poor understanding of its pathogenesis is also reflected in the lack of effective medical treatment. Well-characterized animal models are utterly needed to develop novel pathogenetic concepts and study new treatment strategies. Currently there is no consensus on how to evaluate and characterize potential PSC models, which makes direct comparison of experimental results and effective exchange of study material between research groups difficult. The International Primary Sclerosing Cholangitis Study Group (IPSCSG) has therefore summarized these key issues in a position paper proposing standard requirements for the study of animal models of PSC.
- Published
- 2014
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.